Ingen CEO Live Radio Interview Friday With The Money Channel
CEO Talks About $50M With Export Sales Projections

Press Release
Source: Ingen Technologies, Inc.
On 11:45 am EST, Tuesday November 3, 2009
Buzz up! Print
Companies:Ingen Technologies, Inc.

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss the projected export sales of their new Oxyview Nasal Cannula this Friday, November 6, 2009 at 10:34AM Eastern Standard Time on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The company's recently issued Chinese patent, new distribution and expected ISO certification in December-2009 opens doors in the People's Republic of China. Chronic obstructive pulmonary disease (COPD) is a major epidemic in China, costing that society billions of dollars in health care expenditures and lost productivity from premature (and perhaps unnecessary) deaths every year. In 2000, the total cost of COPD and other smoking-related diseases in China was more than U.S. $5 billion and, in 2000, COPD was the second leading cause of mortality in China, trailing only cerebrovascular disease. Ingen has secured intellectual property rights in China, and upon ISO Certification in December-2009, projects a staggering $25M annual sales revenue in China along by 2012. The company has received an offer for China distribution from a major supplier and this will be announced later this month.



The company's pending European patents expected to issue in 2010, its new introduction at Germany's MEDICA this November-2009 and ISO Certification and CE Mark scheduled for December-2009 triggers generous revenues in Europe starting next year. In Europe estimates suggest that 10% of the population has COPD and is now the 5th leading cause of death in the European Communities. The social healthcare structure throughout Europe and for home oxygen care would recognize the cost savings through the use of the company's Oxyview Nasal Cannula and cost reductions as a result of a decrease in unnecessary home visits. Europe's medical care system indicates at least $25M in annual sales to Ingen by 2012.



The company's ISO Certification in December 2009 also allows its new distributor in Australia, Medical Industries Australia, to begin selling the new Oxyview Nasal Cannula immediately. COPD is costing the nation an estimated $818 to $898 million annually. This is a conservative estimate because it is based on 1993-94 figures extrapolated to the Year 2001. The addition of hidden costs could increase the estimate to more than $1 billion per year. It is the 4th leading cause of death for Australians. Annual sales in Australia should reach $1M by 2012, considering their medical care structure and economy of scale.



A growing elderly population, increase in home oxygen therapy and surgeries and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



"Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M. The export sales are expected to out-perform domestic sales here in the USA as COPD is a more serious problem in China and Europe," Stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



Breaking Down the "Great Wall" of COPD Care in China -- Sin and Tan 176 (8): 732 -- American Journal of Respiratory and Critical Care Medicine



http://www.efanet.org/copd/documents...to-eng_000.pdf



http://www.efanet.org/copd/documents/statistics.pdf



The Australian and New Zealand COPD Reference Site



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

YUCAIPA, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.



A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.



The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.



With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.



With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.



"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Welcome



U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel



http://www.copd-international.com/li...statistics.htm



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.






Contact:
Ingen Technologies, Inc.Jeff Morgan909-790-7180www.info@ingen-tech.com

__________________
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on.

Ingen Announces Projections of $10M in Sales for 2010

YUCAIPA, Calif., Nov 3, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the CEO, Scott Sand, discussed conservative projections for 2010 on The Money Channel's American Scene Radio with host Steve Crowley this past Tuesday.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA will result in demand for better efficiency and cost reductions in medical care. The elderly population in the USA age 75 and older in 2010 is expected to be almost 19M. In 2015 it is expected to increase to 20M, and over the next 30 years will more than double. The Oxyview and Oxyview Nasal Cannula improves home oxygen therapy and reduces supplier costs by decreasing unnecessary service calls, thus reducing government expenditures related to treating COPD.

The World Health Organization (WHO) estimates that COPD as a single cause of death in the world shares 4th and 5th places with HIV/AIDS (after coronary heart disease, cerebrovascular disease and acute respiratory infection). COPD is the fourth leading cause of death in the U.S. and is projected to be the third leading cause of death for both males and females by the year 2020. It is estimated that there may currently be 16 million people in the United States currently diagnosed with COPD, and that there may be as many as an additional 14 million or more in the United States still undiagnosed, as they are in the beginning stages and have little to minimal symptoms and have not sought health care yet. About 1.5 million emergency department visits by adults 25 and older were made for COPD in 2000. The total estimated cost of COPD in 2002 was $32.1 billion. $18 billion were direct costs. $14.1 billion were indirect cost, and it is estimated that the total cost of managing COPD in 1998, physicians, medications, hospital and nursing care, etc., exceeded 15 billion dollars in the United States.

With proper marketing, advertising, branding, distribution and direct sales, Ingen expects to generate $10M in sales. These numbers are based on assumptions and recent historical trends with the company's increase in sales and market acceptance. The ISO 13485 Certification expected in December-2009 will instantly result in large export shipments of the Oxyview and Oxyview Nasal Cannula products. In addition, the company has signed marketing contracts with various firms to activate an immediate direct sales program to oxygen providers, suppliers and COPD support groups in the USA. The sales in 2010 will represent approximately less than 1% of the US market in oxygen cannula sales.

With the new manufacturing revisions, manufacturing costs will decrease approximately by 50%, while this new revision increases quality and efficiency in the manufacture of Oxyview and the Oxyview Nasal Cannula. The prior sales margins of 63% will remain the same while the company passes these manufacturing savings directly to its distribution as an incentive to better compete with the competition.

"With the new auditors in place, and near completion of the required SEC filings, the management is focused in increasing sales and distribution of the Oxyview and Oxyview Nasal Cannula; while we continue to finalize ISO and GSA in the next 2 months. The GSA application was submitted in September-2009 and GSA has informed us that they have undergone internal changes and would respond in the next 30 days. GSA increases our sales in to the VA hospitals, while the ISO certification opens huge doors for exporting our products globally," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

Welcome

U.S. Senior Population Projections by Age (2010-2050) - Bar Charts - Swivel

COPD Statistics

Ingen Technologies,Inc. - Home

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adults, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.

Our Capabilities
We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.
anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls.
Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism.
One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use.
Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,
"...it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance."
An L.A. Times article said,
Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times.
Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:
• NUTRITION AND ENERGY BOOST
While most people notice an energy boost right away, the nutritional results with undernourished people is staggering.
• DETOXIFICATION
In vitro studies show the Moringa’s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way.
• ANTIBIOTIC
Moringa works as a gentle, natural antibiotic,
See Eilert, U.,B. Wolters and A. Nahrstedt. “The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.” Journal of Medicinal Plant Research, 42, pp 55-61. 1981
• SKIN TREATMENT
And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself.
• ANTI-INFLAMMATORY
Indian traditional medicines have long used the Moringa in treating the body’s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, “Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123.
• ULCERS
The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17.
• DIABETES
An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18.
• SLEEP
The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18
In short some studies have proved Moringa leaves effective for treating,
• Blood pressure
• Diabetes
• Colitis and Diarrhea
• Used as a diuretic
• Headache
• Glandular swelling
• Skin antiseptic
• Fevers

everyones going crazy about this ceo stuff, i cannot wait to see what happens when the market opens.

Ingen Receives $100K Purchase Order Today for New Oxyview Nasal Cannula
Sales and Demand for New Products Continue to Increase
Nov 4, 2009 9:00:00 AM
2009 GlobeNewswire, Inc.


Email Story Discuss on ZenoBank

View Additional ProfilesYUCAIPA, Calif., Nov. 4, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.

A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA has resulted in an increase of buyers for Ingen's new Oxyview Nasal Cannula. The company now provides 8 different models of the Oxyview and Oxyview Nasal Cannula. The cannulas are designed for Adults, Pediatrics and Infants, and include 0-6 liters/minute and a low-flow 0-3 liters/minute unit that is either reusable or comes attached to a high quality 7' latex free oxygen tube with a curved soft-tip nasal cannula. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow rate readings for the patient and caregiver.

The company also received very good news today from the COPD Foundation. The November issue of COPD Digest has been printed and shipped and is receiving an excellent response at the American College of Chest Physician's Annual 2009 conference in San Diego, CHEST 2009. Ingen has a full-page color ad in this edition of the COPD Digest and telephone orders and PayPal orders have increased this week.

"We are seeing a strong increase in revenues, and expect this trend to continue over the next several years. Our accountants and auditors are diligently working on completion of the SEC filings, specifically the 10-KSB. We anticipate filing a revised annual and quarterly report on the OTC Pink Sheets later next week. The company is progressing forward very nicely at this time and we will continue to make public announcements as each event occurs," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

__________________
I am not a registered broker and my posts are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.

what a great sell for IGNT i think this is just what it needs for it to have a run today i like this stock alot.Theres been alot of PR will push it through the day.

I am still holding here gang and think IGNT will eventually run well for me. I will hold and possibly add to my position on the small pull backs.

__________________
All my posts are purely my opinion. Please use your own buy and sell signals and never invest in a stock you can not afford to lose money on. For a complete disclaimer click here

IGNT- Hearing Great news @ the close today- stock will hav e good day- and even better tommorow- buy low sell high- go go go!!! Gl to all!

Ingen Brings Aboard CDM Capital to Assist With SEC Reporting Obligations
CEO Live Radio Interview Discusses Improving Shareholder Value

Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EST, Tuesday November 10, 2009

YUCAIPA, Calif., Nov. 10, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has engaged CDM Capital, LLC to assist with the internal financial reporting and controls as they are related to the most current SEC reporting obligations. In addition to this news, CEO Scott Sand will discuss why the company is focused on its investor needs later today, November 10, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.



The Newport Beach-California based CDM Capital LLC offers a wide range of pre and post public entity support services in areas such as structuring, capitalization, public relations, investor relations, financial reporting, compliance, market support and exit strategies. The firm provides additional services related to increasing the valuation, and access the U.S. capital markets by listing it as an Over-the-Counter (OTC) publicly traded company.



Specifically, the company and CDM Capital have engaged in a two month contract where CDM shall render financial consulting services to Ingen in matters relating to the restatement, as necessary, of Ingen's financials for the year ended May 31, 2007 and May 31, 2008, working with Ingen's accounting department, outside service providers, and its auditor to prepare and submit the delinquent SEC Reports (Form 10-Q for the period ended November 30, 2008, Form 10-Q for the period ended February 28, 2009, Form 10-K for the year ended May 31, 2009, and Form 10-Q for the period ended August 31, 2009) and prepare reports and financial statements for posting on Pink Sheets -- Electronic Quotation and Trading System for OTC Securities.



"The company is focused on finalizing the SEC filings and the reports required with the OTC Pinks. The new auditors and CDM Capital have reviewed the events with our previous auditors and are comfortable with preparing the filings that are required. The company has heavily invested in improving its SEC reporting for its shareholders, investors and future shareholders. We will also consider extending CDM Capital's services to include working with our investment banking group, Pacific Pearl Group, with increasing the company's valuation. Keep in mind that there are several opportunities for an acquisition of Ingen by other candidates currently in discussions with Pacific Pearl Group. Part of increasing shareholder value by improving our financial team of experts and moving to the OTC-Bulletin Board," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Services - Microcap Reverse Merger and Financing Advisory



The Money Channel // American Scene Radio // WallStreetCast



Ingen Technologies,Inc. - Home

__________________
I am not a registered broker and my posts are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.